For example, a phase-2 pilot study (NCT01265576) examined ADRB2 inhibition in hepatocellular carcinoma (HCC) patients, where sorafenib was combined with the beta-blocker propranolol and a COX2 inhibitor. Here, ADRB2 is linked to hepatocellular carcinoma.